- Home
- DMA vs SCLX Comparison
DMA vs SCLX Comparison
Compare DMA & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMA
- SCLX
- Stock Information
- Founded
- DMA 2011
- SCLX 2011
- Country
- DMA United States
- SCLX United States
- Employees
- DMA N/A
- SCLX N/A
- Industry
- DMA Trusts Except Educational Religious and Charitable
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- DMA Finance
- SCLX Health Care
- Exchange
- DMA Nasdaq
- SCLX Nasdaq
- Market Cap
- DMA 77.0M
- SCLX 72.5M
- IPO Year
- DMA N/A
- SCLX N/A
- Fundamental
- Price
- DMA $8.61
- SCLX $0.42
- Analyst Decision
- DMA
- SCLX Strong Buy
- Analyst Count
- DMA 0
- SCLX 3
- Target Price
- DMA N/A
- SCLX $11.33
- AVG Volume (30 Days)
- DMA 34.6K
- SCLX 184.3K
- Earning Date
- DMA 01-01-0001
- SCLX 01-17-2025
- Dividend Yield
- DMA 2.04%
- SCLX N/A
- EPS Growth
- DMA N/A
- SCLX N/A
- EPS
- DMA N/A
- SCLX N/A
- Revenue
- DMA N/A
- SCLX $55,152,000.00
- Revenue This Year
- DMA N/A
- SCLX $32.77
- Revenue Next Year
- DMA N/A
- SCLX $50.71
- P/E Ratio
- DMA N/A
- SCLX N/A
- Revenue Growth
- DMA N/A
- SCLX 22.02
- 52 Week Low
- DMA $4.78
- SCLX $0.38
- 52 Week High
- DMA $8.00
- SCLX $2.63
- Technical
- Relative Strength Index (RSI)
- DMA 50.39
- SCLX 38.58
- Support Level
- DMA $8.45
- SCLX $0.40
- Resistance Level
- DMA $8.64
- SCLX $0.53
- Average True Range (ATR)
- DMA 0.12
- SCLX 0.05
- MACD
- DMA 0.02
- SCLX 0.01
- Stochastic Oscillator
- DMA 89.65
- SCLX 27.14
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.